Ocrelizumab Biosimilar (R-Pharm)

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameOcrelizumab Biosimilar (R-Pharm)
Drug Alias NameRPH-035
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAnti-CD20Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesR-Pharm Jsc
China Registration ClassN/A

Develop Information

Active CompaniesR-Pharm Jsc
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A